We are live on ! Find out more
SRRA

Sierra Oncology, Inc. Common Stock

Delisted

SRRA was delisted on the 30th of June, 2022.

34 hedge funds and large institutions have $169M invested in Sierra Oncology, Inc. Common Stock in 2021 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 12 increasing their positions, 5 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

140% more repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 5

50% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 2

13% more capital invested

Capital invested by funds: $150M → $169M (+$19.5M)

3% more funds holding

Funds holding: 3334 (+1)

33% less funds holding in top 10

Funds holding in top 10: 32 (-1)

Holders
34
Holders Change
+1
Holders Change %
+3.03%
% of All Funds
0.59%
Holding in Top 10
2
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-33.33%
% of All Funds
0.03%
New
3
Increased
12
Reduced
5
Closed
2
Calls
Puts
Net Calls
Net Calls Change

SRRA Hedge Fund Activity: Q2 2021 in Review

34 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Sierra Oncology, Inc. Common Stock (SRRA) for Q2 2021, worth a combined $169M — up 13% from $150M a quarter earlier.

Buyers outnumbered sellers: 3 funds opened new SRRA positions and 2 closed out — a net gain of 1 holder — while 12 added to existing stakes and 5 trimmed.

The largest buyer was Ikarian Capital, adding an estimated $1.81M. The largest seller was Millennium Management, cutting an estimated $269K.

  • 34 institutional investors held Sierra Oncology, Inc. Common Stock (SRRA) as of Q2 2021, up from 33 in Q1 2021.
  • Funds reported $169M of Sierra Oncology, Inc. Common Stock stock for Q2 2021, up 13% quarter-over-quarter.
  • 3 funds opened new Sierra Oncology, Inc. Common Stock positions in Q2 2021 and 2 closed out, a net change of +1 holder.
  • The largest Sierra Oncology, Inc. Common Stock buyer in Q2 2021 was Ikarian Capital, an estimated $1.81M added.
  • The largest Sierra Oncology, Inc. Common Stock seller in Q2 2021 was Millennium Management, an estimated $269K sold.

Based on aggregated 13F filings for Q2 2021.